The program that subsidises Soliris® for patients with a rare condition called paroxysmal nocturnal haemoglobinuria (PNH) is changing. Until now, we have subsidised Soliris® under the Life Saving Drugs Program. From 1 March 2022, this will change to the Pharmaceutical Benefits Scheme (PBS).
